RRPV Solicitation Summary: Rapid Antigen Production for Immunoassay Diagnostics (RAPID)

The Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response (ASPR) has issued a Special Notice announcing a Request for Project Proposals (RPP) titled "Rapid Antigen Production for Immunoassay Diagnostics (RAPID)" through the Rapid Response Partnership Vehicle (RRPV) Consortium. This solicitation was posted on April 15, 2026, and represents an opportunity for biotechnology research and development contractors to participate in a government-sponsored initiative. The notice informs potential offerors of the availability of this funding opportunity and directs them to access detailed information through the RRPV website. No set-aside restrictions apply to this solicitation, meaning it is open to all eligible contractors regardless of business size or status. The ASPR, through its Biomedical Advanced Research and Development Authority (BARDA), is managing this procurement effort focused on diagnostic capabilities.

The RAPID initiative seeks to support the advanced research and development of rapid antibody and protein-based molecular recognition reagent generation platforms that can accelerate the production of immunoassay-ready reagents for diagnostic applications. The primary objective is to establish flexible, end-to-end systems capable of generating high-performance binders against both known and emerging biological threats, with the goal of compressing development timelines from pathogen sequence identification to assay-ready reagents within weeks. Interested contractors must submit proposals by the May 13, 2026 deadline and are strongly encouraged to participate in the Proposer's Conference and Teaming Connect scheduled for April 27, 2026, from 11:00 AM to 12:00 PM EST, which will be conducted virtually. Full details regarding the RPP, conference registration, and consortium participation information are available through www.rrpv.org. This opportunity falls under the Research and Development in Biotechnology classification (NAICS 541714) and targets contractors with capabilities in health-related research and development services.